Treatment of antipsychotic-induced hyperprolactinemia: an update on the role of the dopaminergic receptors D2 partial agonist aripiprazole.

Treatment of antipsychotic-induced hyperprolactinemia: an update on the role of the dopaminergic receptors D2 partial agonist aripiprazole.
Recent Pat Endocr Metab Immune Drug Discov. 2014 Jan;8(1):30-7
Authors: De Berardis D, Fornaro M, Serroni N, Marini S, Piersanti M, Cavuto M, Valchera A, Mazza M, Girinelli G, Iasevoli F, Perna G, Martinotti G, Di Giannantonio M
Abstract
Hyperprolactinemia is an unwanted adverse effect present in several typical and atypical antipsychotics. Aripiprazole is a drug with partial agonist activity at the level of dopamine receptors D2, which may be effective for antipsychotic- induced hyperprolactinemia. Therefore, we analyzed the literature concerning the treatment of antipsychoticinduced hyperprolactinemia with aripiprazole by updating a previous paper written on the same topic. More recent studies were reviewed. They showed that there are two options for the treatment of antipsychotic-induced hyperprolactinemia with aripiprazole. The safest strategy may require the addition of aripiprazole to ongoing treatments, in the case patients had previously responded to antipsychotic drugs and then developed hyperprolactinemia. However, it is advisable to monitor the patients in case relapses and/or side effect, although rare, might occur. Switching drugs should be considered when a patient does not appear to be responding to the previous antipsychotic, thus developing hyperprolactinemia. A cross-taper switc...

Source: Recent Patents on Endocrine, Metabolic and Immune Drug Discovery - June 4, 2015 Category: Endocrinology Tags: Recent Pat Endocr Metab Immune Drug Discov Source Type: research